Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-007024
Date:2021-01-31
Issuer: TRAVERE THERAPEUTICS, INC. (TVTX)
Original Submission Date:

Reporting Person:

CLAGUE LAURA
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-01-31 A 5,000 a $0.00 39,473 direct
COMMON STOCK 2021-02-02 S 2,500 d $30.75 36,973 direct
COMMON STOCK 2021-02-02 S 1,125 d $30.75 35,848 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 on january 31, 2020, the reporting person was granted a performance restricted stock unit (prsu) grant covering 10,000 shares of the issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. on january 31, 2021, a portion of the prsus vested upon the 12 month anniversary of the date of grant, following the issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the duplex study.
f2 the sales reported in this form 4 were made pursuant to a written plan meeting the requirements of rule 10b5-1(c) of the securities exchange act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
f3 the sales reported in this form 4 were made pursuant to a written plan meeting the requirements of rule 10b5-1(c) of the securities exchange act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Elevate your investments